• Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

  NCT07475403

  RecruitingInterventionalPhase 2Updated May 26, 2026
• Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC

  NCT07749924

  Not yet recruitingInterventionalNot ApplicableUpdated Aug 6, 2026
• Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration

  NCT07307456

  RecruitingInterventionalPhase 2Updated Jul 21, 2026
• Investigation Into the Integration of Intracavitary Cryoablation and Immunotherapy in Bladder-Preserving Therapy

  NCT07204132

  RecruitingInterventionalNot ApplicableUpdated Oct 2, 2025
• Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer

  NCT05445648

  Unknown statusInterventionalPhase 2Updated Dec 28, 2022
• NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment

  NCT06537154

  RecruitingInterventionalPhase 2Phase 3Updated Jul 30, 2025

ClinicalTrials.gov ID

NCT07625527

Lead Sponsor

Tianjin Medical University Second HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

120Estimated

Last Update Posted

Jun 4, 2026Actual

Start Date

May 30, 2026Estimated

Primary Completion Date

Mar 30, 2029Estimated

Completion Date

May 30, 2032Estimated

Official Title

Randomized Trial of Active Surveillance Versus Continued Systemic Immunotherapy After Achieving Tumor-Free Status in Extensive Transurethrally Unresectable Very-High-Risk NMIBC

Brief Summary

Patients with extensive transurethrally unresectable very-high-risk non-muscle-invasive bladder cancer (NMIBC) may achieve a tumor-free status after systemic immunotherapy-based bladder-sparing treatment combined with transurethral resection of bladder tumor (TURBT). However, the optimal duration of systemic immunotherapy after achieving a tumor-free status remains uncertain. Prolonged treatment may increase toxicity, treatment burden, and cost, while some patients may maintain durable disease control without continued therapy.

This randomized study aims to evaluate whether active surveillance after achieving tumor-free status is a feasible alternative to continued systemic immunotherapy in patients with extensive transurethrally unresectable very-high-risk NMIBC.

Patients will initially receive systemic immunotherapy-based treatment followed by disease evaluation using cystoscopy with biopsy and/or TURBT, urine cytology, urinary tumor DNA (utDNA), and imaging assessments. Patients who achieve tumor-free status after treatment and complete resection of visible disease will be randomized to either active surveillance or continued systemic immunotherapy.

The study will evaluate recurrence outcomes, bladder preservation, progression, safety, and patient management strategies following achievement of tumor-free status. The trial also aims to explore the role of urinary tumor DNA in identifying patients who may safely undergo treatment de-escalation and active surveillance.

• Bladder (Urothelial, Transitional Cell) Cancer
• Non Muscle Invasive Bladder Cancer

• Active Surveillance
• PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria

• Has histologically confirmed very-high-risk non-muscle-invasive urothelial carcinoma of the bladder.

• Has transurethrally unresectable bladder tumor, defined as visually incomplete TURBT and/or extensive high-volume disease considered unsuitable for complete and oncologically adequate transurethral resection.

• Has undergone cystoscopy and TURBT evaluation before study enrollment.

• Has received systemic PD-1/PD-L1 inhibitor-based bladder-sparing therapy before randomization.

• Has achieved tumor-free status before randomization, defined as:

  1. No visible bladder tumor on cystoscopy;
  2. Negative bladder biopsy and/or TURBT pathology;
  3. Negative urine cytology;
  4. Negative urinary tumor DNA (utDNA);
  5. No radiographic evidence of progression or metastasis.

• Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

• Has adequate organ function.

• Has provided written informed consent.

Cohort A Only

• Achieved tumor-free status at the initial response evaluation after induction systemic therapy.
• Maintained tumor-free status after additional systemic therapy before randomization.

Cohort B Only

• Did not achieve tumor-free status at the initial response evaluation because of residual non-muscle-invasive disease.
• Subsequently underwent complete TURBT/resection of residual disease followed by additional systemic therapy.
• Achieved tumor-free status at the second response evaluation before randomization.

Exclusion Criteria

• Has muscle-invasive bladder cancer (≥T2), locally advanced unresectable disease, nodal disease, or distant metastasis.
• Has concurrent upper tract urothelial carcinoma.
• Has persistent visible tumor, positive bladder pathology, positive urine cytology, or positive utDNA before randomization.
• Has received prior systemic immunotherapy for metastatic urothelial carcinoma.
• Has active autoimmune disease requiring systemic treatment.
• Is receiving systemic immunosuppressive therapy.
• Has uncontrolled infection requiring systemic therapy.
• Has another active malignancy requiring systemic treatment.
• Has known active hepatitis B, hepatitis C, human immunodeficiency virus infection, or active tuberculosis.
• Has pregnancy or breastfeeding.
• Has any medical or psychiatric condition that, in the investigator's judgment, would interfere with study participation or interpretation of results.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Tianjin Medical University Second HospitalOTHER

zgb2016@163.com+8613903124399

wjluro@163.com+8617299180245